Considerations in gender-affirming hormone therapy in transgender and gender diverse patients undergoing liver transplantation.
Nikzad N, Fisher A, et al. • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2024
The transplant community is ethically obligated to address the health care gap in managing gender-affirming hormone therapy (GAHT) for transgender and gender diverse patients undergoing liver transplantation, and tangible steps can be taken to improve health outcomes for this minoritized patient population.
Key Findings
Background
Management of gender-affirming hormone therapy during the perioperative period of liver transplantation is unknown and without clear guidelines.
No established protocols exist for GAHT management in liver transplant candidates and recipients.
The paper identifies this as a 'health care gap' that the transplant community is ethically obligated to address.
The authors note that GAHT can be lifesaving for TGGD patients who experience gender dysphoria, parallel to the lifesaving role of transplantation for end-stage liver disease.
Background
Gender-affirming hormone therapy plays an integral role in the care of transgender and gender diverse liver transplant candidates and recipients.
The authors characterize GAHT as potentially 'lifesaving' for TGGD patients experiencing gender dysphoria.
The paper calls for the transplant community to 'acknowledge the integral role of GAHT in the care of TGGD liver transplant candidates and recipients.'
TGGD patients are described as a 'minoritized patient population' with distinct healthcare needs.
Discussion
The transplant community is described as ethically obligated to address healthcare gaps in GAHT management for TGGD liver transplant patients.
The authors review current literature to support the ethical obligation framing.
The paper argues that 'profound strides can be made in improving care for TGGD patients through gender-affirming care and appropriate management of GAHT in liver transplantation.'
The ethical obligation is presented as a central thesis requiring action from the transplant community.
Conclusions
The authors propose tangible clinical steps to improve health outcomes for TGGD patients undergoing liver transplantation.
The paper suggests 'tangible steps that clinicians may take to improve health outcomes for this minoritized patient population.'
Recommendations are directed at the broader transplant community, not just individual clinicians.
The paper frames these steps within the context of gender-affirming care principles.
Nikzad N, Fisher A, Pillai A, Targownik L, Te H, Aronsohn A, et al.. (2024). Considerations in gender-affirming hormone therapy in transgender and gender diverse patients undergoing liver transplantation.. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. https://doi.org/10.1016/j.ajt.2024.05.002